🔥 Monday 27 April 2026 Mon, 27 Apr 2026

Icetana AI reported a 51% year-on-year jump in annual recurring revenue to $2.6 million but faced a $1.2 million net operating cash outflow in Q3 FY26, prompting plans for a capital raise amid expected cash flow improvements.

Castile Resources has kicked off pilot plant bench scale testing for its Rover 1 project, integrating a 41% resource upgrade and higher metal prices into its Bankable Feasibility Study. The company also secured $8.4 million in funding and is preparing for exploration drilling amid regional consolidation.

AuKing Mining has bolstered its project portfolio with the acquisition of a Tasmanian tin and silver licence and the Malawi-based Tundulu Rare Earths Project, supported by $5 million in recent equity placements.

FINEOS Corporation Holdings PLC reported its strongest quarterly cash inflow ever alongside key contract wins in Australia and North America, maintaining its FY26 revenue guidance and advancing AI integration in its insurance software platform.

Sabre Resources (ASX:SBR) has secured 80% stakes in two companies holding nearly 4,000km² of highly prospective gold and copper-gold projects in the Northern Territory, including drill-ready targets analogous to the Tennant Creek Mineral Field. A heavily supported $2 million placement will fund aggressive exploration including imminent drilling.

Paradigm Biopharmaceuticals has upsized a $14 million placement and launched a $2 million SPP, boosting its cash runway to around $45 million. This capital injection supports the ongoing Phase 3 trial for knee osteoarthritis, with interim results expected in Q3 2026.

Flynn Gold has reported standout assay results from its Tasmanian projects, including exceptional silver-lead-zinc grades at Silver King and significant tungsten-gold mineralisation at Firetower and Warrentinna, underpinning a ramp-up in drilling and regional exploration.

PYC Therapeutics has gained Orphan Drug Designation from the European Medicines Agency for its VP-001 candidate targeting Retinitis Pigmentosa type 11, enhancing its regulatory and commercial pathway in Europe.

Island Pharmaceuticals has cleared a major regulatory hurdle with the US FDA, confirming a clinical development path for its antiviral Galidesivir under the Animal Rule. Backed by a $9 million capital raise and strategic partnerships, the company is poised for potential US government procurement and biodefence market entry.

Albright Metals delivers strong high-grade gold results from its Golden Pike Project in Canada while boosting its balance sheet through a $1.8 million tenement sale to Catalyst Metals, sharpening its focus on high-impact assets.

Corella Resources has agreed to acquire a majority interest in the Chobe Project, expanding its footprint in Western Australia’s emerging rare earths and niobium hotspot. The acquisition is backed by a heavily oversubscribed $5 million capital raise.

Corella Resources has agreed to acquire a majority interest in the Chobe Project, a highly prospective niobium and rare earths ground in Western Australia’s West Arunta, supported by a heavily oversubscribed $5 million capital raise.

Forrestania Resources has reported a series of high-grade gold intercepts from drilling at British Hill, Mt Palmer, and Johnson Range projects in Western Australia, underscoring its methodical exploration approach and potential resource growth.

Chimeric Therapeutics' CHM CORE-NK cell therapy achieved a 60% complete response rate in high-risk frontline AML patients, significantly exceeding typical outcomes and maintaining a strong safety profile.

Diamond Infraco 1 Pty Ltd, backed by IFM Global Infrastructure Fund, has tabled an all-cash takeover offer for the remaining Atlas Arteria securities at A$4.75, rising to A$5.10 if a 45% stake is secured. The bid comes amid concerns over Atlas Arteria’s recent strategic pivot and operational underperformance.

Brazilian Rare Earths (ASX: BRE) has reported substantial expansion of its Monte Alto rare earth project with ultra high-grade drilling results and validated low-temperature processing delivering 97% recovery. The company also secured a Trial Mining Licence enabling early production and bulk shipments.

AML3D has maintained a steady $2.2 million quarterly revenue run rate and secured $12.5 million in new orders during 3Q26, pushing its total orders for FY2026 to $29 million. The company is aggressively expanding its US manufacturing footprint and making initial inroads into UK and European defence markets.

IperionX has transitioned its Virginia titanium operations to continuous 24/7 production, ramping proprietary HAMR™ titanium powder output to 4.2 metric tons in March and targeting 200 tons per annum by the end of 2026. Alongside manufacturing capacity expansions and strong U.S. Department of War backing, the company advances its critical minerals project in Tennessee.

Altair Minerals has landed a A$28.2 million strategic placement from Endeavour Mining’s subsidiary at a premium, boosting its treasury to about A$40 million and enabling a major expansion of exploration at the Greater Oko gold project in Guyana.

Solstice Minerals has pushed the boundaries of its Nanadie Copper-Gold Project in WA, completing the deepest drillhole to date and logging visible copper sulphides well below previous resource levels. Assay results are pending, but early signs point to meaningful extensions of the mineralised system.

HITIQ Limited's March quarter saw a remarkable 223% jump in sales to $294k, driven by the nationwide rollout of its PROTEQT™ concussion management system and initial international sales. The company bolstered its governance and advisory ranks while managing funding to support its commercial push.

AdNeo (ASX:AD1) delivered its first positive operating cash flow quarter since its 2025 transformation, driven by strong revenue growth across all divisions and a growing $8m tender pipeline. The company advances its AI-first strategy while managing costs and acquisitions.

Barton Gold Holdings has reported exceptional high-grade gold assays up to 170 g/t at its Challenger project and strong drilling progress at Tunkillia, underpinning an advancing feasibility study and a robust cash balance of $13.3 million.

Sunshine Metals reveals a robust Mining Study at its Liontown Project in Queensland, targeting shallow oxide gold with initial production of approximately 75,000 ounces of gold and 654,000 ounces of silver, generating an estimated net operating cashflow of $163 million. High-grade drilling results and a $202K government grant support ongoing exploration and development.